TrialSite has emphasized the importance of research in the fight against COVID-19 and many other infectious diseases and other threats to humanity. Recently, researchers from the Tokyo University of Science (along with scientists from the National Institute of Infectious Diseases, Kyushu University, The University of Tokyo, Kyoto University, Japanese Foundation for Cancer Research, and Science Groove Inc.)―have identified an anti-malarial drug, mefloquine (which is incidentally a derivative of hydrochloroquine), that is effective against SARS-CoV-2. Their findings are published in Frontiers in Microbiology. In a breakthrough study, a team of scientists―comprising Dr. Koichi Watashi, Kaho Shionoya, Masako Yamasaki, Dr. Hirofumi Ohashi, Dr. Shin Aoki, Dr. Kouji Kuramochi, and Dr. Tomohiro Tanaka―identified mefloquine as the drug with the highest anti-SARS-CoV-2 activity among the tested compounds. In fact, when comparing in a lab environment—that is, study in cell line involving humanized lung cells, the drug was superior to other quinoline derivatives such as hydroxychloroquine.